Li Mei-Ling, Shih Shin-Ru, Tolbert Blanton S, Brewer Gary
Department of Biochemistry and Molecular Biology, Rutgers Robert Wood Johnson Medical School, Piscataway, NJ 08854, USA.
Research Center for Emerging Viral Infections, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan.
Vaccines (Basel). 2021 Feb 27;9(3):199. doi: 10.3390/vaccines9030199.
Enterovirus A71 (EV-A71) is a major causative agent of hand, foot, and mouth disease (HFMD) and herpangina. Moreover, EV-A71 infection can lead to neurological complications and death. Vaccination is the most efficient way to control virus infection. There are currently three inactivated, whole EV-A71 vaccines licensed by the China NMPA (National Medical Products Administration). Several other types of vaccines, such as virus-like particles and recombinant VP1 (capsid protein), are also under development. In this review, we discuss recent advances in the development of EV-A71 vaccines.
肠道病毒A71型（EV - A71）是手足口病（HFMD）和疱疹性咽峡炎的主要病原体。此外，EV - A71感染可导致神经并发症和死亡。接种疫苗是控制病毒感染的最有效方法。目前有三种由中国国家药品监督管理局（NMPA）批准的EV - A71全病毒灭活疫苗。其他几种类型的疫苗，如病毒样颗粒和重组VP1（衣壳蛋白）也在研发中。在本综述中，我们讨论了EV - A71疫苗研发的最新进展。
